[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609236":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":26,"responsibleParty":70,"collaborators":10,"id":72,"slug":10,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":10,"maxAge":79,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Consorci Sanitari de l'Alt Penedès i Garraf","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tofacitinib",null,"Patients affected by JIA and treated with tofacitinib",[13],"Drug: Tofacitinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Noemí Casaponsa","CONTACT","+34938960025","43197","recerca@csapg.cat",[27,43,56],{"facility":28,"status":10,"city":29,"state":29,"zip":10,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Hospital Sant Joan de Déu Barcelona","Barcelona","Spain",{"type":32,"coordinates":33},"Point",[34,35],2.15899,41.38879,{"lat":35,"lon":34},[38,41],{"name":39,"role":22,"phone":40,"phoneExt":10,"email":25},"Andrea Zacarías Crovato","+34 93 253 21 00",{"name":39,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":44,"status":10,"city":45,"state":29,"zip":10,"country":30,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Corporació Sanitària Parc Taulí de Sabadell","Sabadell",{"type":32,"coordinates":47},[48,49],2.10942,41.54329,{"lat":49,"lon":48},[52,55],{"name":53,"role":22,"phone":54,"phoneExt":10,"email":25},"Judith Sánchez Manubens","+34937231010",{"name":53,"role":42,"phone":10,"phoneExt":10,"email":10},{"facility":57,"status":10,"city":58,"state":59,"zip":60,"country":30,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Hospital de Vilafranca","Vilafranca del Penedès","Barceona","08720",{"type":32,"coordinates":62},[63,64],1.69713,41.34618,{"lat":64,"lon":63},[67,68],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},{"name":69,"role":42,"phone":10,"phoneExt":10,"email":10},"Vicenç Torrente, Ph.D.",{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100609236",false,"NCT07211932","Tofacitinib in Juvenile Idiopathic Arthritis","Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.","Inclusion criteria:\n\nDiagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.\n\nDocumentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.\n\nAge under 18 years at the time of the treatment indication with tofacitinib.\n\nExclusion criteria:\n\nParticipants diagnosed with any of the following conditions:\n\nReactive arthritis\n\nArthritis associated with inflammatory bowel disease\n\nArthritis associated with another autoimmune disease","ALL","18 Years",{"count":81,"type":82},58,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.",[86],"Juvenile Idiopathic Arthritis (JIA)",[88,89,90],"Arthritis, Juvenile","tofacitinib [Supplementary Concept]","Janus Kinase Inhibitors","NOT_YET_RECRUITING","2025-11-21",{"date":94,"type":95},"2025-11-26","ACTUAL",{"date":97,"type":82},"2025-12",{"date":99,"type":82},"2026-12",{"name":5,"class":6},3]